# TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

> **NCT06818058** · PHASE2 · RECRUITING · sponsor: **Tarian Pharma** · enrollment: 60 (estimated)

## Conditions studied

- EGFR Inhibitor-associated Rash

## Interventions

- **DRUG:** Brimonidine tartrate Gel
- **DRUG:** Placebo gel (no Brimonidine tartrate)

## Key facts

- **NCT ID:** NCT06818058
- **Lead sponsor:** Tarian Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06818058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06818058, "TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06818058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*